Cancer reports (Hoboken, N.J.) · 2026
Adverse Prognostic Significance of Activation-Induced Cytidine Deaminase in Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hardianti Mardiah Suci, Anggorowati Nungki, Setiawan Syahru Agung, Bagaskoro Miraz Radhea, Kurnianda Johan, Taroeno-Hariadi Kartika Widayati, Purwanto Ibnu, Hutajulu Susanna Hilda
Аннотация
BACKGROUND: A number of studies have demonstrated the important role of activation-induced cytidine deaminase (AID) in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). AID has been relatively underexplored as a prognostic factor in DLBCL, and its role remains controversial.
AIMS: This study conducted a comprehensive analysis of the association between AID expression and clinical outcomes in 70 Indonesian patients with DLBCL treated with a standard CHOP ± rituximab regimen.
METHODS AND RESULTS: Immunostaining results showed that AID was expressed in 35.7% of DLBCL samples. Multivariate analysis indicated that positive AID expression was associated with shorter overall survival (OS) specifically among patients receiving a rituximab-containing regimen, with a hazard ratio of 10.39 (95% CI: 1.93-55.96; p = 0.006).
CONCLUSION: The significant prognostic value of AID in the DLBCL subgroup treated with rituximab-but not in the general DLBCL population or in those not receiving rituximab-underscores the potential relevance of AID expression in DLBCL management and treatment decisions.
AIMS: This study conducted a comprehensive analysis of the association between AID expression and clinical outcomes in 70 Indonesian patients with DLBCL treated with a standard CHOP ± rituximab regimen.
METHODS AND RESULTS: Immunostaining results showed that AID was expressed in 35.7% of DLBCL samples. Multivariate analysis indicated that positive AID expression was associated with shorter overall survival (OS) specifically among patients receiving a rituximab-containing regimen, with a hazard ratio of 10.39 (95% CI: 1.93-55.96; p = 0.006).
CONCLUSION: The significant prognostic value of AID in the DLBCL subgroup treated with rituximab-but not in the general DLBCL population or in those not receiving rituximab-underscores the potential relevance of AID expression in DLBCL management and treatment decisions.